* Unclear when Humira biosimilar would start sales (Adds background on Samsung Bioepis)
SEOUL, July 18 Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group, said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion10
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner6
21:31 Time Warner jumps after hours on report it could sell for $110 per share to AT&T1
10:31 Gloom Falls Over Samsung as Phone Group Frets Lost Bonuses, Jobs2